Floatz logo

Blinatumomab

Acute Lymphoblastic Leukemia, Pediatric

Institute of Hematology & Blood Diseases Hospital, Chinamonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

70 Active assets in the Acute Lymphoblastic Leukemia, Pediatric cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
MERCAPTOPURINE ANHYDROUS
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →
precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →